Sustained drug-free remission in rheumatoid arthritis associated with diffuse large B-cell lymphoma following tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy using zamtocabtagene autoleucel
David Szabo, Alexandra Balogh, László Gopcsa, Laura Giba-Kiss, Gergely Lakatos, Melinda Paksi, Marienn Réti, Péter Takács, Pearl van Heteren, Gregor Zadoyan, Silke Holtkamp, Toon Overstijns, Stefan Miltenyi, Péter Reményi, György Nagy
Abstract
We report the case of long-term persisting rheumatoid arthritis (RA), treated with CD20-CD19 CAR-T when it became associated with diffuse large B cell lymphoma (DLBCL), resulting in a sustained drug-free remission of the preceding RA, as well as of the subsequent DLBCL that formed the indication of the CAR-T therapy using zamtocabtagene autoleucel, with a 1-year follow-up. According to our best knowledge, this is the first published clinical case report of long-term persisting RA treated with CAR-T cell therapy.